Paratek Pharmaceuticals (NASDAQ:TSPT) Given Daily News Sentiment Score of 0.06

Headlines about Paratek Pharmaceuticals (NASDAQ:TSPT) have trended somewhat positive on Monday, Accern Sentiment Analysis reports. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Paratek Pharmaceuticals earned a media sentiment score of 0.06 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 46.3744543818097 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Shares of Paratek Pharmaceuticals (TSPT) opened at $21.65 on Monday. Paratek Pharmaceuticals has a 1-year low of $12.45 and a 1-year high of $29.00.

TRADEMARK VIOLATION NOTICE: “Paratek Pharmaceuticals (NASDAQ:TSPT) Given Daily News Sentiment Score of 0.06” was first posted by The Ledger Gazette and is the property of of The Ledger Gazette. If you are viewing this news story on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this news story can be viewed at

Paratek Pharmaceuticals Company Profile

Paratek Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics based upon tetracycline chemistry. Its product candidates are the antibacterials omadacycline and sarecycline. Omadacycline is an antibiotic being developed for use as an empiric monotherapy option for patients suffering from serious, community-acquired bacterial infections.

Insider Buying and Selling by Quarter for Paratek Pharmaceuticals (NASDAQ:TSPT)

Receive News & Ratings for Paratek Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Paratek Pharmaceuticals Inc and related companies with's FREE daily email newsletter.

Leave a Reply